Page contentsKey factsDecisionKey facts Active Substance gotistobart Therapeutic area Neoplasms benign, malignant and unspecified (incl cysts and polyps) Decision number P/0498/2023 PIP number EMEA-003467-PIP01-23 Pharmaceutical form(s) All pharmaceutical forms Condition(s) / indication(s) Treatment of lung cancer Route(s) of administration All routes of administration Contact for public enquiries E-mail: admin@oncoc4.comTel. +1 (202)7516823 Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 01/02/2023DecisionP/0498/2023 : EMA decision of 1 December 2023 on the granting of a product specific waiver for gotistobart, (EMEA-003467-PIP01-23)AdoptedReference Number: EMA/517080/2023 English (EN) (185.1 KB - PDF)First published: 14/02/2025ViewShare this page